The company integrates biology and chemistry to unlock targets and pathways validated through genomic medicine as root causes or major drivers of human cancers. FORMA's innovative drug discovery technologies and oncology expertise enable the screening, discovery, and rational development of a generation of small molecule drug candidates with cellular mechanisms of action. The company builds a pipeline of therapeutics directed at Achilles heels in human cancers, such as key targets associated with cancer stem cells, tumor cell metabolism, programmed cell death, or epigenetic disease mechanisms. FORMA leverages its innovative drug discovery platform to address challenging targets and develop a robust internal pipeline of breakthrough oncology drugs.